

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF
THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
BY AN OFFEROR OR AN OFFEREE

1. KEY INFORMATION

| | |
|---|--------------------------|
| (a) Full name of discloser: | AMGEN INC. |
| (b) Owner or controller of interests and short positions disclosed, if different from 1(a): <i>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</i> | N/A |
| (c) Name of offeror/offeree in relation to whose relevant securities this form relates: <i>Use a separate form for each offeror/offeree</i> | HORIZON THERAPEUTICS PLC |
| (d) Is the discloser the offeror or the offeree? | OFFEROR |
| (e) Date position held: <i>The latest practicable date prior to the disclosure</i> | 12 DECEMBER 2022 |
| (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? <i>If it is a cash offer or possible cash offer, state "N/A"</i> | N/A |

2. INTERESTS AND SHORT POSITIONS

If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates (Note 1)

| Class of relevant security: Ordinary shares of \$0.0001 each in the capital of Horizon Therapeutics plc | | | | |
|--|------------------|----------|------------------------|----------|
| | Interests | | Short positions | |
| | Number | % | Number | % |
| (1) Relevant securities owned and/or controlled: | Nil | - | Nil | - |
| (2) Cash-settled derivatives: | Nil | - | Nil | - |
| (3) Stock-settled derivatives (including options) and agreements to purchase/ sell: | Nil | - | Nil | - |
| Total: | Nil | - | Nil | - |

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3. INTERESTS AND SHORT POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE

| Details of any interests and short positions (including directors' and other employee options) of any person acting in concert with the party making the disclosure: | | |
|---|-------------------------------------|---|
| Concert Party Details | Interest Details | Percentage of Issued Ordinary Shares |
| Robert A. Eckert Living Trust (a related trust of Robert A. Eckert, a director of Amgen Inc.) | 86 ordinary shares of \$0.0001 each | 0.000038% |

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

(c) Attachments

| | |
|---|-----------|
| Is a Supplemental Form 8 attached? | NO |
|---|-----------|

| | |
|----------------------------|-------------------------|
| Date of disclosure: | 13 December 2022 |
| Contact name: | Arvind Sood |
| Telephone number: | +1 805 447 1060 |

Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service.